Koers Enzymatica AB Nasdaq Stockholm
Aandelen
SE0003943620
Farmaceutische producten
Omzet 2024 * | 6,04 mln. 66,11 mln. 5,65 mln. | Omzet 2025 * | 11,85 mln. 130 mln. 11,08 mln. | Marktkapitalisatie | 48,71 mln. 533 mln. 45,55 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -5 mln. -54,7 mln. -4,68 mln. | Nettowinst (verlies) 2025 * | -1 mln. -10,94 mln. -935K | EV/omzet 2024 * | 8,59 x |
Nettoschuld 2024 * | 3,18 mln. 34,82 mln. 2,98 mln. | Nettoliquiditeiten 2025 * | 2,05 mln. 22,45 mln. 1,92 mln. | EV/omzet 2025 * | 3,94 x |
K/w-verhouding 2024 * |
-16,5
x | K/w-verhouding 2025 * |
-35,1
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 34,79% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Ulf Thomas Blom
FOU | Founder | 59 | 01-01-07 |
Claus Egstrand
CEO | Chief Executive Officer | 63 | 18-07-17 |
Director of Finance/CFO | 55 | 01-01-18 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Bengt Baron
CHM | Chairman | 62 | 19-12-16 |
Director/Board Member | 56 | 15-02-16 | |
Director/Board Member | 57 | 01-05-21 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+25,83% | 661 mld. | |
+27,00% | 566 mld. | |
-6,76% | 352 mld. | |
+20,34% | 332 mld. | |
+3,00% | 283 mld. | |
+13,09% | 231 mld. | |
+5,46% | 200 mld. | |
-9,61% | 195 mld. | |
-6,26% | 145 mld. |